Adirondack Research & Management’s Harvard Bioscience HBIO Stock Holding History

Adirondack Research & Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$628K	Sell	9,002 -940	-9%	-$74.8K	0.76%	56
2021 Q2	$828K	Sell	9,942 -3,561	-26%	-$252K	0.97%	46
2021 Q1	$737K	Buy	13,503 +834	+7%	+$40.6K	0.87%	53
2020 Q4	$544K	Sell	12,669 -6,380	-33%	-$238K	0.74%	51
2020 Q3	$573K	Hold	19,049	–	–	0.8%	45
2020 Q2	$591K	Buy	19,049 +6,425	+51%	+$173K	0.78%	43
2020 Q1	$279K	Sell	12,624 -480	-4%	-$13K	0.39%	61
2019 Q4	$400K	Hold	13,104	–	–	0.35%	66
2019 Q3	$403K	Sell	13,104 -23,640	-64%	-$588K	0.35%	71
2019 Q2	$735K	Sell	36,744 -6,757	-16%	-$198K	0.53%	54
2019 Q1	$1.88M	Sell	43,501 -11,791	-21%	-$427K	1.17%	31
2018 Q4	$1.76M	Buy	55,292 +6,360	+13%	+$251K	1.1%	35
2018 Q3	$2.57M	Buy	48,932 +6,215	+15%	+$349K	0.96%	46
2018 Q2	$2.29M	Buy	42,717 +9,468	+28%	+$485K	0.89%	49
2018 Q1	$1.66M	Buy	+33,249	New	+$1.49M	0.67%	59

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Adirondack Research & Management's HBIO Position: Q3 2021 in Review

Adirondack Research & Management reduced its Harvard Bioscience (HBIO) stake by 9.5% in Q3 2021, selling an estimated $74.8K and leaving 9,002 shares worth $628K. The position accounts for 0.76% of the portfolio, ranked #56.

Adirondack Research & Management first reported a position in HBIO in Q1 2018 and has held it in 15 quarters since. The position peaked at $2.57M in Q3 2018. 99 funds tracked by Wall St. Rank hold HBIO as of Q3 2021.

Adirondack Research & Management held 9,002 shares of Harvard Bioscience worth $628K as of Q3 2021.
Adirondack Research & Management sold 940 Harvard Bioscience shares in Q3 2021, an estimated $74.8K.
Harvard Bioscience made up 0.76% of Adirondack Research & Management's portfolio in Q3 2021, its #56 holding.
Adirondack Research & Management first reported a position in Harvard Bioscience in Q1 2018 and has held it in 15 quarters since.
Adirondack Research & Management's Harvard Bioscience position peaked at $2.57M in Q3 2018.
99 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2021.

Based on Adirondack Research & Management's 13F filing for Q3 2021, filed 29 Oct 2021.